Literature DB >> 18819994

PARP inhibitors and cancer therapy - early results and potential applications.

C Jones1, E R Plummer.   

Abstract

Polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are emerging as an exciting new class of agents for treating cancer. There is pre-clinical evidence for their use to potentiate both chemotherapeutic agents and radiotherapy, and also as single agents. This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18819994     DOI： 10.1259/bjr/30872348

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  7 in total

Review 1.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

Review 2.  New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Authors:  Susanne Burdak-Rothkamm; Kevin M Prise
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

Review 3.  Our changing view of the genomic landscape of cancer.

Authors:  Daphne W Bell
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

Review 4.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Authors:  Rajasekharan Somasundaram; Jessie Villanueva; Meenhard Herlyn
Journal:  Adv Pharmacol       Date:  2012

Review 5.  Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Authors:  Ruth Plummer
Journal:  Breast Cancer Res       Date:  2011-08-16       Impact factor: 6.466

6.  New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules.

Authors:  Yu-Ru Lee; Dah-Shyong Yu; Ya-Chun Liang; Kuo-Feng Huang; Shih-Jie Chou; Tsung-Chih Chen; Chia-Chung Lee; Chun-Liang Chen; Shih-Hwa Chiou; Hsu-Shan Huang
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

7.  Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.

Authors:  Ruth Plummer; Peter Stephens; Louiza Aissat-Daudigny; Anne Cambois; Gilbert Moachon; Peter D Brown; Mario Campone
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-01       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.